5.16 Cardiac events after four years of a normal perfusion scintigraphy in diabetic women

Smanio, P.; Beraldo, Pedro; Mello, Ronaldo Peixoto de; Rodrigues, Fernando; Thom, A.; Piegas, Leopoldo Soares

doi:10.1016/j.nuclcard.2005.06.016

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, such aggressive treatment without prognostic testing may be justified as even normal SPECT MPS with technetium-99m-sestamibi in diabetic women was associated with an increased risk of cardiac events over a 4-year followup period [18]. This small case-control, database study of consecutive female patients compared 33 diabetic with 127 nondiabetic women and found an annual hard event (death or nonfatal MI) rate of 3.0% compared with 0.6% annual, respectively.…”

Section: Diabetes Mellitusmentioning

confidence: 93%

Noninvasive monitoring of medical therapy

Kudes

Schwartz

2006

Curr Cardiol Rep

View full text Add to dashboard Cite

An extensive literature base documents the substantial incremental prognostic value of nuclear cardiology compared with information provided by risk factors, clinical history, electrocardiographic stress testing results, and coronary arteriography. A smaller, well-established and growing literature addresses the unique potential of nuclear cardiology to assess therapeutic response of ischemic heart disease to lifestyle and medical therapies in individual patients. General guidelines focus on management of individual risk factors based on large studies, but may not reflect the optimum treatment strategy for an individual patient. The central rationale for noninvasive serial monitoring is to optimize the effectiveness and timing of lifestyle, medical, and revascularization therapies to minimize coronary event risk. Ideally, this monitoring of therapy should be early in the management of coronary artery disease (CAD) and guide the need for more intensive therapeutics. The application of technical advances in serial monitoring has the potential to revolutionize the way we diagnose and prevent CAD, even in asymptomatic patients. The potential long-term cost effectiveness of positron emission tomography and single-photon emission CT myocardial perfusion scintigraphy in detecting and monitoring treatment of CAD offers great promise for reducing coronary events in known or suspected ischemic heart disease.

show abstract

Section: Diabetes Mellitusmentioning

confidence: 93%